Figure 1From: Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial Estimated curves of overall survival and time to progression. At a median follow-up of 40.5 months (95% CI, 36.4–44.6 months), the median time to progression was 6.6 months (95% CI, 3.9–9.4 months) and the median overall survival was 22.9 months (95% CI, 17.2–28.5 months).Back to article page